Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Antidepressant effects of ketamine in depressed patients
Autore:
Berman, RM; Cappiello, A; Anand, A; Oren, DA; Heninger, GR; Charney, DS; Krystal, JH;
Indirizzi:
Connecticut Mental Hlth Ctr, Clin Neurosci Res Unit, Abraham Ribicoff Ctr,New Haven, CT USA Connecticut Mental Hlth Ctr New Haven CT USA icoff Ctr,New Haven, CT USA W Haven Vet Affairs Med Ctr, Affect Disorders Program, Dept Psychiat, New Haven, CT USA W Haven Vet Affairs Med Ctr New Haven CT USA Psychiat, New Haven, CT USA Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA Yale Univ New Haven CT USA iv, Sch Med, Dept Psychiat, New Haven, CT USA
Titolo Testata:
BIOLOGICAL PSYCHIATRY
fascicolo: 4, volume: 47, anno: 2000,
pagine: 351 - 354
SICI:
0006-3223(20000215)47:4<351:AEOKID>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
NMDA RECEPTOR ANTAGONISTS; IMIPRAMINE; PHARMACOTHERAPY; CLOMIPRAMINE; ADAPTATION; TOLERANCE; MODEL; RATS;
Keywords:
major depression; N-methyl-D-aspartate antagonist; excitatory amino acids; randomized clinical trial;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
25
Recensione:
Indirizzi per estratti:
Indirizzo: Berman, RM Connecticut Mental Hlth Ctr, Clin Neurosci Unit, Rm 360,34 Pk St, New Haven, CT 06519 USA Connecticut Mental Hlth Ctr Rm 360,34 Pk St New Haven CT USA 06519
Citazione:
R.M. Berman et al., "Antidepressant effects of ketamine in depressed patients", BIOL PSYCHI, 47(4), 2000, pp. 351-354

Abstract

Background: A growing body of preclinical research suggests that brain glutamate systems may be involved in the pathophysiology, of major depression and the mechanism of action of antidepressants, This is the first placebo-controlled double-blinded trial to assess the treatment effects of a single dose of an N-methyl-D-aspartate (NMDA) receptor antagonist in patients withdepression,Methods: Seven subjects with major depression completed 2 rest days that involved intravenous treatment with ketamine hydrochloride (.5 mg/kg) or saline solutions under randomized, double-blind conditions. Results: Subjects with depression evidenced significant improvement in depressive symptoms within 72 hours after ketamine but not placebo infusion (i.e,, mean 25-item Hamilton Depression Rating Scale scores decreased by 14 +/- SD 10 points vs. 0 +/- 12 points, respectively during active and sham treatment). Conclusions: These results suggest a potential role for NMDA receptor-modulating drugs in the treatment of depression. Biol Psychiatry 2000;47:351-354 (C) 2000 Society of Biological Psychiatry.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/01/20 alle ore 21:25:29